262 results about "Psychiatric Disease" patented technology

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more intracranial (IC) stimulating electrodes in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.

A magnetic stimulation apparatus for central nervous system and circuit thereof and use of the apparatus and method of using the apparatus are shown. Controlling circuit design and outputting wave form signal to a drive power supply circuit enables the drive power supply circuit to output current of corresponding wave form to coils, and by means of the design of the shape, number of turns, size, interval of the coils, generates within a certain region inside the coils a desired time-variant magnetic field which is then applied to the brain of an animal or a human being so that the central nervous system can receive a wide area synergy magnetic stimulation with a precise wave form, high frequency or a combination of a plurality of frequency components, thus achieving the treatment of nervous and psychiatric diseases or brain function improvement in combination with behavior guidance, thought guidance, or psychological guidance.

A method, apparatus, and surgical technique for the modulation of autonomic function, for the purpose of treating any of several conditions and diseases, including obesity, metabolic disorders, endocrine disorders, diabetes, respiratory disease, asthma, inflammatory disease, immunological disease, infection, cancer, cardiac disease, cardiovascular disease, cerebrovascular disease, stroke, vasospasm, vascular disease, psychiatric disease, depression, affective disorders, anxiety disorders, and other conditions. This includes neural and tissue modulators, including implanted devices, used to modulate efferent and afferent autonomic neurons to influence or control autonomic or other neural function, including modulation of sympathetic and parasympathetic nervous system components as well as their combination.

Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

The present invention pertains to compositions and methods for therapeutically and / or prophylactically treating patients with neurological, neurogenetic, or psychiatric diseases, disorders, conditions, or distress. Specifically, the present invention relates to the administration of compositions containing vitamins B6 and E, magnesium oxide, essential fatty acids, and folate.

Hypodermic syringes with multiple needles are used to practice a method of calming psychiatric patients. In accordance with one embodiment of the invention generally used to calm violent adult patients, the syringe has a first barrel containing an antipsychotic, a second barrel containing a sedating antihistamine and a third barrel containing an antianxiety sedative. Each barrel also has a separate projecting needle and contains a piston. A common operator, preferably in the form of a plunger simultaneously pushes all of the pistons so that the patient receives three injections simultaneously. For children, a second embodiment of the syringe includes two barrels instead of three, each barrel containing a separate medication. In each embodiment the syringe is packaged in a manually openable plastic envelope with a safety cap over the needles.

Compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed:wherein R1-R8, G, N and A− are as defined in the written description.

Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and / or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.

Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

Exemplary method, system and computer-accessible medium can be provided for diagnosing at least one disease and / or a subtype within a disease. For example, it is possible to determine at least one region of interest, and obtain a plurality of data points associated with each of such region(s) of interest. It is also possible to identify a particular pattern of the data points across each of such region(s) of interest. Further, it is possible, e.g., using a computer arrangement, to determine a likelihood of the disease(s) and / or the subtype by comparing the particular pattern to at least one known pattern.

The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

The present invention relates to an injectable, pharmaceutical composition comprising a C1-6 alkyl ester of a C10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.

The invention disclosed herein relates to methods and systems for modulating activity of a nervous system component. Neural pattern recognition is used to identify a neurological and / or psychiatric disease or disorder based on input generated by electric signals indicative of the subject's brain activity. In an embodiment, the method comprises receiving an input from one or more sensors, each sensor configured to sense a particular characteristic indicative of a neurological or psychiatric condition or state; developing treatment parameters based on the input received from the one or more sensors; and generating neural modulation signals for delivery to a nervous system component through one or more output devices in accordance with one or more developed treatment parameters.

The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.

The invention relates to a non-human mammal animal model of neurological and psychiatric diseases and a preparation method and application thereof. A mouse model provided by the invention is in high similarity with the model of human neurological and psychiatric diseases. A neurological and psychiatric diseases drug screening platform based on the animal model can be used in new drug screening and development of other treatments.

The present invention provides a method for modulating or regulating levels of a neurochemical in an individual using deep brain stimulation. More particularly, the invention relates to a method of treating neurological and psychiatric diseases by providing a feedback loop capable of maintaining central and / or peripheral nervous system neurochemical levels in an individual.

A method of diagnosing depression in a subject, comprising analyzing a biological sample from a subject in need of diagnosis of depression for the expression of spadin, detecting and measuring the amount of spadin in the sample, and diagnosing depression in the subject if an increase or a decrease in spadin expression in the biological sample is detected compared to a control, is described as are methods for monitoring treatment, remission and the course of the disease. Related kits are also described. Also described is a method for identifying candidate compounds for treating depression.

The present disclosure describes the use of genetic variance information for genes involved in neurologic and phychiatric diseases and in the selection of effective methods of treatment of such disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

The present invention relates to a novel class of substituted phenylpiperazinyl derivatives having the formula (I) wherein X, Z, Y, U,V, Alk, W, R<1> , R<2>, R<3>, R<11>, R<12>, R<13> n, m and the dotted line are as defined in the description. The compounds of the invention are dopamine D4 receptor ligands and are therefore useful for the treatment of certain psychiatric and neurologic disorders, including psychosis.

The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.

The invention discloses a psychiatric disease auxiliary diagnosis system based on virtual reality technology and physiological parameter detection. The system comprises a patient terminal device and adoctor terminal device; the patient terminal device comprises a physiological parameter monitoring module, a VR / AR interaction module and a data acquisition and processing module; the VR / AR interaction module induces a user to generate special behaviors and mood fluctuations by displaying specific scenes to the user; the physiological parameter monitoring module is used for acquiring various physiological parameter data of the user in real time; acquired data are transmitted to the doctor terminal device through the Internet; the doctor terminal device includes a real scene acquisition module, a communication and control module, a tracking module and a display module, wherein the display module displays various indicators and behavior interaction modes of the user; and therefore, auxiliary diagnosis can be completed. According to the system, the VR / AR technology and physiological parameter monitoring are combined, and therefore, diagnostic accuracy can be improved, and the preventionand early treatment of psychiatric diseases can be benefitted.

The invention discloses a wearable multimode brain function detection device based on NIRS-EEG. The wearable multimode brain function detection device comprises an NIRS-EEG detection unit, an ultra-low power consumption control unit, a state prompt unit, a Bluetooth communication unit, a key input unit and a power supply unit; the ultra-low power consumption control unit is connected with the NIRS-EEG detection unit, the state prompt unit and the Bluetooth communication unit respectively, the ultra-low power consumption control unit conducts data instruction communication with the NIRS-EEG detection unit through SPI interfaces, the ultra-low power consumption control unit conducts data transmission communication with the Bluetooth communication unit through a UART serial port communication protocol, and the Bluetooth communication unit sends received data to a mobile terminal for subsequent processing; the key input unit is connected with the power supply unit, and the power supply unit is used for supplying power to the NIRS-EEG detection unit, the ultra-low power consumption control unit, the state prompt unit and the Bluetooth communication unit and conducting power supply protection and power management. The wearable multimode brain function detection device has good comfortability, and monitoring on occasions such as the brain cognitive function, neurological and psychiatric diseases and sleep and fatigue states can be conveniently conducted anytime and anywhere.

The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.

The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.

The invention belongs to the field of neurological and psychiatric gene detection and particularly relates to a high-throughout sequencing method of genes relative to neurological and psychiatric drugs and application of the high-throughout sequencing method. The invention provides the high-throughout sequencing method of the genes relative to the neurological and psychiatric drugs and the application of the high-throughout sequencing method. The method comprises the following steps of acquisition of a genome DNA, target gene multiplex PCR amplification reaction and product purification, linker sequence PCR reaction and product purification, library detection, high-throughout sequencing and the like. The method can be used for detecting 29 SNP loci of 20 genes relative to drugs for neurological and psychiatric diseases at one time, can cover a vast majority of first-line and second-line drugs for resisting schizophrenia, depression, anxiety, epilepsy, Parkinson's disease, hyperkineticdisorder, pains and the like and provides guidance to medication of a patient to the maximum.

The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.

The present invention provides methods for evaluating the pharmacological efficacy of drugs or drug candidates in treatment of psychiatric diseases or disorders, particularly schizophrenia, and for predicting the efficacy of drugs or drug combinations indicated for treatment of both positive and negative symptoms of psychiatric diseases or disorders in an individual having such a disease or disorder. In both methods, the drugs or drug candidates evaluated are assessed for their ability to produce certain changes in the expression of specific genes in peripheral mononuclear cells in blood of psychiatric patients, which are similar to the changes obtained following treatments with reference drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.

Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.